"We are very pleased to reach this important milestone and with such an encouraging rate of enrollment in our CRB-701 program," said Dr. Dominic Smethurst, MA MRCP, Chief Medical Officer of Corbus. "CRB-701 data demonstrates differentiated safety, tolerability and efficacy profiles in HNSCC, cervical and mUC tumors." The three-part Phase 1 study (NCT06265727) is evaluating the safety, pharmacokinetics and efficacy of CRB- 701 in participants with advanced solid tumors associated with high Nectin-4 expressio ...